S. Pogam

发表

Pharmacokinetic / Pharmacodynamic Predictors of Clinical Potency for 1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3

T. Lavé, M. Reddy, P. N. Morcos, 2012 .

Inhibitors of the Hepatitis C Virus Palm-Binding Nonnucleoside Polymerase Variants Dually Resistant to Thumb-and Selection and Characterization of Replicon

Than, C. Oshiro, A. M. Giannetti, 2006 .

1 Slow-binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus

A. M. Giannetti, S. Harris, S. Pogam, 2009 .

Analogs than to Nonnucleoside Polymerase Higher Barrier to Resistance to Nucleoside the Hepatitis C Virus Replicon Presents A

J. Symons, S. Pogam, N. Cammack, 2008 .

Alone or in Combination with Pegylated Interferon-a 2 a and Ribavirin Prevents Hepatitis C Virus ( HCV ) Replication and Selection of Resistant Variants in HCV-Infected Patients

A. Kosaka, S. Pogam, N. Cammack, 2010 .

Design and Characterization of R1626, A Prodrug of the HCV Replication Inhibitor R1479 (4′-Azidocytidine) With Enhanced Oral Bioavailability

G. Dore, Xiaoyang Wu, D. Shaw, 2007 .

Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis

C. Stedman, T. Hassanein, E. Gane, 2016, Hepatology International.

21 LOW LEVEL OF RESISTANCE, LOW VIRAL FITNESS AND ABSENCE OF RESISTANCE MUTATIONS IN BASELINE QUASISPECIES MAY CONTRIBUTE TO HIGH BARRIER TO R1626 RESISTANCE IN VIVO

A. Kosaka, J. Symons, S. Pogam, 2008 .

958 NO EVIDENCE OF R7128 DRUG RESISTANCE AFTER UP TO 4 WEEKS TREATMENT OF GT 1, 2 AND 3 HEPATITIS C VIRUS INFECTED INDIVIDUALS

A. Kosaka, S. Pogam, I. Nájera, 2009 .

62 ACTIVITY OF DANOPREVIR PLUS LOW-DOSE RITONAVIR (DNV/R) IN COMBINATION WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN (PEGIFNa-2A/RBV) IN PREVIOUS NULL RESPONDERS

B. Gujral, E. Gane, D. Larrey, 2011 .

Nosocomial Transmission of Hepatitis C Virus

Y. Bacq, S. Pogam, Alain Gondeau, 1999, Annals of Internal Medicine.

Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors.

Amy D. Fung, N. Arora, S. Harris, 2010, Bioorganic & medicinal chemistry letters.

Characterization of Hepatitis C Virus (HCV) Quasispecies Dynamics upon Short-Term Dual Therapy with the HCV NS5B Nucleoside Polymerase Inhibitor Mericitabine and the NS3/4 Protease Inhibitor Danoprevir

A. Kosaka, D. Chin, S. Pogam, 2012, Antimicrobial Agents and Chemotherapy.

Intracellular Effects of the Hepatitis C Virus Nucleoside Polymerase Inhibitor RO5855 (Mericitabine Parent) and Ribavirin in Combination

S. Fletcher, S. Pogam, S. Le Pogam, 2014, Antimicrobial Agents and Chemotherapy.

The kinetics of antibodies against hepatitis C virus may predict viral clearance in exposed hemophiliacs.

Y. Gruel, Y. Bacq, A. Goudeau, 1998, The Journal of infectious diseases.

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients

C. Boucher, R. D. de Knegt, H. Janssen, 2017, Scientific Reports.

[602] INHIBITION OF HCV REPLICATION BY PSI-6130: CHARACTERIZATION OF ACTIVITY IN THE HCV REPLICON SYSTEM

J. Symons, S. Pogam, N. Cammack, 2007 .

Hepatitis C in a Hemodialysis Unit: Molecular Evidence for Nosocomial Transmission

R. Christen, A. Goudeau, S. Pogam, 1998, Journal of Clinical Microbiology.